Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1

Article Clinical Neurology

Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Inge M. W. Verberk et al.

Summary: Pre-analytical sample handling can impact Alzheimer's disease blood-based biomarkers. Different collection tube types resulted in varying values of assessed markers, with delayed centrifugation and storage affecting A beta and t-tau. Standardized operating procedures for plasma handling were constructed to facilitate the incorporation of blood-based biomarkers into research and clinical settings.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Article Clinical Neurology

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis

Zoe Y. G. J. van Lierop et al.

Summary: This study investigated serum contactin-1 (sCNTN1) as a potential biomarker for disease progression in natalizumab-treated RRMS patients. The results suggest that lower baseline sCNTN1 concentrations were associated with long-term disability progression during natalizumab treatment.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Article Clinical Neurology

Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: This study found that GFAP and p-tau have good diagnostic and longitudinal monitoring potential in preclinical Alzheimer's disease. Combining GFAP with other proteins can improve diagnostic accuracy.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Article Clinical Neurology

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

Tomas Uher et al.

Summary: The study found that combining sNfL with NEDA-3 status can better identify patients at higher risk of future disease activity. Patients with high sNfL levels are more likely to experience disease activity in the following year and show greater whole brain volume loss.

MULTIPLE SCLEROSIS JOURNAL (2021)

添加到收藏夹

Article Oncology

Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases

Su-Hyun Kim et al.

Summary: This study evaluated the roles of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) in diagnosing and monitoring brain metastases. Both sNfL and sGFAP showed significant differences in levels between patients with and without BMs, and combining the two biomarkers improved sensitivity to up to 98%. The levels of sNfL and sGFAP were related to BM size and changed with BM progression and treatment, suggesting their potential as biomarkers for BM screening in cancer patients.

CANCERS (2021)

添加到收藏夹

Article Clinical Neurology

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

Whitley W. Aamodt et al.

Summary: The study found that neurofilament light chain protein (NfL) is associated with cognitive function in Parkinson's disease (PD) patients and can predict future cognitive decline. Plasma NfL was identified as a useful prognostic biomarker for PD, predicting the likelihood of PD patients converting to mild cognitive impairment or dementia.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Seven day pre-analytical stability of serum and plasma neurofilament light chain

Patrick Altmann et al.

Summary: The study found that the soluble serum and plasma NfL concentration remains stable when unprocessed blood samples are stored up to 7 days at room temperature, which is crucial for ensuring reliable study protocols.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Clinical Neurology

Serum Contactin-1 in CIDP A Cross-Sectional Study

Luuk Wieske et al.

Summary: The study found that serum contactin-1 levels were lower in CIDP patients with paranodal antibodies compared to those without, suggesting it may serve as a possible diagnostic biomarker for paranodal injury in CIDP. This provides class II evidence that serum contactin-1 levels can discriminate between CIDP patients with or without paranodal antibodies with 71% sensitivity and 97% specificity.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

添加到收藏夹

Article Medicine, Research & Experimental